The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
Subscribe To Our Newsletter & Stay Updated
